FitLife Brands, Inc. (FTLF) stock analysis
Close on Nov 11, 2026Market cap $78.13MP/E 43.8Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak4 of 30 checks passed
FitLife Brands passes 4 of the 30 checks behind our score; 12 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 0/6
- Past performance
- 2/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
P/B below the industry
FitLife Brands's price-to-book of 1.65 is below the Drugs median of 2.29.
Return on equity above the industry
FitLife Brands's return on equity of 4.4% is above the Drugs median of -58.9%.
Net margin above the industry
FitLife Brands's net margin of 1.9% is above the Drugs median of -53.0%.
Short-term assets cover short-term debts
Current assets are 1.46 times current liabilities.
What to watch
Margin of safety under 20%
The price is 15.6% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $8.32 is above our fair value estimate of $7.20.
Return on equity under 15%
Return on equity was 4.4% over the last twelve months and averaged 23.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 6.1%, below the 10% that usually covers the cost of capital.
Valuation1/6
P/E above its 5-year median
FitLife Brands's P/E of 43.8 is above its own 5-year median of 18.6.
P/E above the industry
FitLife Brands's P/E of 43.8 is above the Drugs median of 25.1.
EV/EBITDA above its 5-year median
FitLife Brands's EV/EBITDA of 17.6 is above its 5-year median of 13.4.
P/B below the industry
FitLife Brands's price-to-book of 1.65 is below the Drugs median of 2.29.
Trading above fair value
The share price of $8.32 is above our fair value estimate of $7.20.
Margin of safety under 20%
The price is 15.6% above fair value, so there is no margin of safety.
Growth0/6
Revenue growing under 10% a year
Revenue grew -17.9% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -23.4% a year over the last three fiscal years.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance2/6
Return on equity under 15%
Return on equity was 4.4% over the last twelve months and averaged 23.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 6.1%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
FitLife Brands's return on equity of 4.4% is above the Drugs median of -58.9%.
Earnings shrank over 5 years
Net income shrank 25.6% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 1.9% over the last twelve months, against a 5-year average of 14.3%.
Net margin above the industry
FitLife Brands's net margin of 1.9% is above the Drugs median of -53.0%.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest not well covered
Operating income covers interest expense 3.4 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 1.46 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.29; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
FitLife Brands has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$7.20
The share price is 16% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 21.8× | 18.6× | 25.1× | $4.15 | 40% |
| EV/EBITDA | 15.2× | 13.4× | 17.1× | $7.23 | 35% |
| P/B | 2.9× | 3.6× | 2.3× | $14.84 | 10% |
| Earnings power | 7.4% cost of equity | – | – | $10.17 | 15% |
| Fair value | $7.20 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 18.6
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $102.45K
- Value traded per 1% price move
- $45.56K
Downside
High risk
- Typical loss in a bad month
- 33.7%
- Volatility (annualized)
- 50%
- Sharpe ratio, 1 year
- -1.20
- Beta to the S&P 500 (5Y)
- 0.27
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -75.3% | -17.9% | -6.3% | -1.2% | |
| Gross profit | -75.5% | -17.0% | -6.3% | +0.9% | |
| Operating income | -77.5% | -19.6% | -7.4% | – | |
| Net income | -77.5% | -23.1% | -25.6% | – | |
| EPS, diluted | -78.0% | -23.4% | -27.1% | – | |
| Free cash flow | -22.9% | +21.4% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 6.7% | 118.1% | 5.1% | |
| Return on assets | 2.2% | 77.9% | 2.4% | |
| Current ratio | 1.77 | 2.84 | 1.53 | |
| Debt to equity | 3.15 | – | – | |
| Net debt to EBITDA | 3.00× | – | – | |
| Interest coverage | 4.3× | 289.7× | 13.6× | |
| Inventory turnover | 3.6× | 3.7× | 0.6× | |
| Capex to revenue | 0.1% | – | 0.3% | |
| Diluted shares | 8M | 9M | 10M |
Cash use needs five years of cash flow figures
FitLife Brands does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 12.7% | 0.19× | 2.07× | 5.1% |
| FY2024 | 13.9% | 1.13× | 1.80× | 28.4% |
| FY2023 | 10.0% | 1.30× | 1.67× | 21.9% |
| FY2022 | 15.4% | 1.22× | 1.22× | 22.9% |
| FY2021 | 19.4% | 1.46× | 1.30× | 37.0% |
| FY2020 | 39.9% | 1.95× | 1.52× | 118.1% |
| FY2019 | 13.6% | 3.10× | 2.37× | 100.3% |
| FY2018 | 3.0% | 2.59× | 4.33× | 33.5% |
| FY2017 | 2.9% | 1.60× | 12.19× | 55.8% |
| FY2016 | 1.5% | 1.54× | 2.99× | 6.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$2.02M
- Cash generatingOperating cash flow above zero$7.44M
- Return on assets improvedROA up on the prior year16.2% → 3.4%
- Earnings backed by cashOperating cash flow above net income$7.44M vs $2.02M
- Less leverageLong-term debt to assets fell14.6% → –
- Better liquidityCurrent ratio rose1.60 → 1.53
- No dilutionShare count did not rise10M → 10M
- Gross margin improvedGross margin up on the prior year43.56% → 43.14%
- More efficientAsset turnover rose1.16 → 0.27
See a number that looks wrong?